Partnerships Factor Bioscience Limited (exclusive License & Collaboration Agreement, September 2024; exclusive licenses in cancer, autoimmune disorders and rare diseases; milestone, royalty and sublicensing payments); MD Anderson Cancer Center (preclinical/EDP collaboration)
Indications
Ovarian cancer (platinum-resistant ovarian cancer)(Preclinical)
Catalysts
— third quarter of 2026
— fourth quarter of 2026
Status note Lead product candidate; IND-enabling studies underway with planned IND submission in 2026; pre-IND regulatory alignment with FDA on development approach.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.